IVVD240517P2500
- 0.35
- 0.000.00%
Invivyd Newsroom
Express News | Invivyd Elects Two New Independent Members to Its Board of Directors
Express News | HC Wainwright & Co. Reiterates Buy on Invivyd, Maintains $15 Price Target
Invivyd Analyst Ratings
Date Upside/Downside Analyst Firm Price Target Change Rating Change Previous / Current Rating 05/14/2024 532.91% HC Wainwright & Co. → $15 Reiterates Buy → Buy 04/05/2024 279.75% Guggenheim → $9 Upgra
Strong Buy Rating for Invivyd Amidst Potential EUA Approval and Promising Revenue Projections
Invivyd to Participate at the H.C. Wainwright 2nd Annual BioConnect Investor Conference
WALTHAM, Mass., May 13, 2024 (GLOBE NEWSWIRE) -- Invivyd, Inc. (NASDAQ:IVVD), a biopharmaceutical company devoted to delivering protection from serious viral infectious diseases, today announced that Marc Elia,
Earnings Call Summary | Invivyd(IVVD.US) Q1 2024 Earnings Conference
The following is a summary of the Invivyd, Inc. (IVVD) Q1 2024 Earnings Call Transcript:Financial Performance:Invivyd ended Q1 2024 with cash and cash equivalents of $189.4 million.The company did not
Invivyd Inc (IVVD) Reports Q1 2024 Financial Results: A Detailed Analysis
Express News | Invivyd Inc : Jefferies Cuts Target Price to $2.9 From $3.5
Invivyd | 10-Q: Quarterly report
Express News | Invivyd Inc - Company Expects to End 2024 With at Least $75 Mln in Cash and Cash
Invivyd 1Q Loss/Shr 38c >IVVD
Invivyd 1Q Loss/Shr 38c >IVVD
Express News | Invivyd Reports First Quarter 2024 Financial Results and Recent Business Highlights
Press Release: Invivyd Reports First Quarter 2024 Financial Results and Recent Business Highlights
Invivyd Reports First Quarter 2024 Financial Results and Recent Business Highlights -- Launched PEMGARDA(TM) in the U.S. for COVID-19 pre-exposure prophylaxis (PrEP) in certain adults and ad
Express News | Invivyd To Pursue Rapid Immunobridging Pathway To Potential EUA For Treatment Of COVID-19 In Moderately To Severely Immunocompromised People, Based On U.S. FDA Feedback
Express News | Invivyd Inc - Potential Near-Term Covid-19 Treatment Eua and Associated Commercial Dynamics Were Not Considered for FY Guidance
Express News | Invivyd Inc - Invivyd Leaves 2024 Net Product Revenue and Year-End Cash Guidance Unchanged
Express News | Invivyd Inc - Company Anticipates Submitting a Covid-19 Treatment Eua Application for Pemgarda™ (Pemivibart) Imminently
Invivyd to Host Conference Call Discussing First Quarter 2024 Financial Results and Business Highlights
WALTHAM, Mass., May 02, 2024 (GLOBE NEWSWIRE) -- Invivyd, Inc. (NASDAQ:IVVD), a biopharmaceutical company devoted to delivering protection from serious viral infectious diseases, today announced that it will host a
Express News | Invivyd Inc: Now Expects to End 2024 With at Least $75 Mln in Cash and Cash Equivalents
Invivyd Announces $20 Million to $25 Million Improvement in Projected 2024 Year-End Cash Position
Improvements realized through comprehensive resource realignment ensuring robust investment in the commercial launch of PEMGARDATM and the discovery of novel monoclonal antibodiesCompany now expects to end 2024 with at